Syndax Pharmaceuticals Inc

Latest Results (12.10.2025):

Syndax Pharmaceuticals Inc. reported its financial results for the second quarter of 2025, showcasing significant growth in its key product revenues and maintaining a strong cash position. The company is progressing toward profitability with robust sales of Revuforj® and Niktimvo™, supported by strategic collaborations and ongoing clinical developments.

Revenue Growth

In Q2 2025, Revuforj® (revumenib) achieved a net revenue of $28.6 million, marking a 43% increase compared to Q1 2025. Additionally, Niktimvo™ (axatilimab-csfr) generated $36.2 million in net revenue in its first full quarter post-launch, with Syndax contributing $9.4 million from collaboration revenue with Incyte.

Strong Cash Position

Syndax Pharmaceuticals Inc. reported having $517.9 million in cash, cash equivalents, and investments, which is expected to fund the company through to profitability. This robust financial position underscores Syndax's ability to support ongoing operations and future growth initiatives.

Product Development and Approvals

The company received Priority Review from the FDA for its supplemental New Drug Application (sNDA) for Revuforj® targeting R/R mNPM1 AML, with a PDUFA action date set for October 25, 2025. Revuforj® continues to show promising results in clinical trials, reinforcing its potential as a first-in-class therapy in the menin inhibitor space.

Operational Highlights

Syndax hosted a conference call on August 4, 2025, to discuss the second quarter results and business updates. CEO Michael A. Metzger highlighted the strong sales momentum of Revuforj® and Niktimvo™, along with the company's strategic initiatives aimed at expanding its franchise and achieving long-term profitability.

Upcoming Milestones

The company is advancing multiple clinical trials for Revuforj® and Niktimvo™, with several expected to report data by the end of 2025. These milestones include pivotal Phase 3 trials and combination therapy studies, which are critical for expanding the indications and market presence of Syndax's therapeutic offerings.